Vyteris Inc. (VYTR) news stock charts
Vyteris Inc. (VYTR/VYTR.OB) Investment Summary:
Vyteris, Inc. develops systems to transdermally deliver peptide and small molecule drugs. Its Smart Patch transdermal technology is used to deliver a peptide molecule in humans without the use of needles. The company offers LidoSite, a topical delivery system, indicated for use on normal intact skin to provide local anesthesia prior to needle stick procedures, such as venipunctures, injections, and intravenous therapies for arthritis and oncology patients, as well as superficial dermatological procedures. Its LidoSite is also used in physician office, hospitals, and commercial diagnostic laboratories. The company is also developing products using its Smart Patch transdermal technology for fe...www.vyteris.com
26 Employees
Founded in 2000
VYTERIS INC (VYTR:OTC Bulletin Board Market)
LAST $0.45 USD
CHANGE TODAY -0.05 -10.00%
VOLUME 267.0
As of 9:30 AM 03/12/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of VYTERIS INC (VYTR)
|
OPEN
$0.45
|
PREVIOUS CLOSE
$0.50
|
|
|
DAY HIGH
$0.45
|
DAY LOW
$0.45
|
|
|
52 WEEK HIGH
10/2/09 - $1.40
|
52 WEEK LOW
03/20/09 - $0.10
|
|
|
MARKET CAP
4.6M
|
AVERAGE VOLUME 10 D
4.3K
|
|
|
EPS TTM
$-0.84
|
SHARES OUTSTANDING
10.3M
|
|
|
VYTR Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for VYTERIS INC (VYTR)
Vyteris Inc. Appoints Eugene A. Bauer as Chairman of the Board
02/17/2010
Vyteris Inc. announced the appointment of Eugene A. Bauer, M.D. as chairman of the company's board of directors. Dr. Bauer is the president and chief medical officer of Peplin Inc.
Vyteris, Inc. Receives Notice from Ferring Pharmaceuticals, Inc. of its Termination of the License and Development Agreement
12/28/2009
Vyteris, Inc. received notice from Ferring Pharmaceuticals, Inc. of its termination of the License and Development Agreement by and between the company and Ferring, effective 30 days from the date of the notice. Upon a termination by Ferring under the Agreement, the following disposition of intellectual property associated with the agreement shall occur: all licenses and other rights granted to the company shall, subject to the continued payment to Ferring of certain royalty payments be converted to and continue as exclusive, worldwide irrevocable, perpetual, sub-licensable licenses to develop, make, have made, use, sell, offer to sell, lease, distribute, import and export the Product; all licenses and other rights granted to Ferring under the Agreement shall be terminated as of the effective date of the termination, excluding any license rights granted pursuant to which shall remain in effect, but shall be restricted to preclude the practice by Ferring of such rights in the field of the iontophoretic administration of the infertility hormone; Ferring shall grant to the company an irrevocable, perpetual, exclusive, royalty-free, sub-licensable license to practice certain intellectual property jointly developed under the Agreement with respect to the iontophoretic administration of infertility hormone; Ferring shall cease to use and shall assign to Vyteris all of its right, title and interest in and to all clinical, technical and other relevant reports, records, data, information and materials relating exclusively to the Product and all regulatory filings (including any NDA, 510(k) or similar regulatory filing) relating exclusively to the Product and provide to Vyteris one (1) copy of each physical embodiment of the aforementioned items within thirty (30) days after such termination and Ferring shall cease to use any Know-How, Information or Materials arising under this Agreement to the extent such Know-How, Information or Materials is owned by Ferring shall promptly return to Vyteris all such materials.
Vyteris Inc., Annual General Meeting, Jul 15, 2009
05/21/2009
Vyteris Inc., Annual General Meeting, Jul 15, 2009, at 10:00 Eastern Daylight. Location: 13-01 Pollitt Drive, Fair Lawn, NJ 07410, United States. Agenda: To consider the election of seven directors of the company to serve until the expiration of their terms and thereafter until their successors have been duly elected and qualified; to consider proposal to increase the number of authorized shares of the company's common stock from 33,333,333 shares to 400,000,000 shares and to conduct other business if properly raised at the meeting or any adjournment thereof.
Vyteris Inc. financial resources
VYTR Competitors
| Company | Last | Change |
| Dynatronics Corp | $1.00 USD | +0.0499 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | VYTR | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.3x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
VYTR |
||
|
VYTR transactions
| Type Date |
Target |
|
Private Placement
February 2, 2010 |
-- |
|
Private Placement
October 30, 2009 |
-- |
More Recent Financial News About Vyteris Inc.
Vyteris Announces Restructuring of Its Balance Sheet Through a $2.3 Million Non-Dilutive Capital Raise and Conversion of Approximately $20 Million of Debt and Preferred Shares Into Common Stock
2010-02-19 05:04:58
Quote: VYTRNews), developer of the
first FDA-approved active transdermal drug delivery system and a leader in
active transdermal drug delivery technology, announced today the sale of
$2.3 million of net operating tax losses in a non-dilutive capital raise
and the conversion of approximately $20 million of debt and preferred
shares into common stock through an agreement with Spencer Trask Specialty
Group LLC.These efforts were completed as part of the Company's ongoing
financial restructuring and overal...Read article
Vyteris Appoints Dr. Eugene A. Bauer as Chairman of the Board
2010-02-19 05:04:57
Quote: Haro Hartounian, president and chief executive officer of Vyteris. "We welcome him to the Vyteris board and look forward to his contributions.""Vyteris' highly versatile and validated transdermal drug delivery technology has broad potential in multiple indications, with applications in the delivery of peptides and proteins and the ability to address complex drug delivery needs," stated Dr. Bauer. "The company has the opportunity to create significant value from this innovative technology through...Read article
Vyteris Announces Private Placement of $1.06 Million of Senior Subordinated Convertible Notes
2010-02-19 05:04:57
Quote: VYTRNews), developer of the
first FDA-approved active transdermal drug delivery system and a leader in
active transdermal drug delivery technology, announced today the private
placement of $1,060,000 of Senior Subordinated Convertible Promissory Notes
due 2013."This financing is a vote of confidence from investors in our strategic
plan," said Haro Hartounian, Ph.D., president and chief executive officer
of Vyteris."Over the past three months, our financial restructuring
efforts have raised a tot...Read article
VYTERIS, INC. Files SEC form 8-K, Financial Statements and Exhibits
2010-02-18 01:23:51
Quote: VYTERIS, INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
VYTERIS, INC.
17-Feb-2010Financial Statements and ExhibitsPrivacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors, incompleteness,
or de...Read article
Vyteris Appoints Dr. Eugene A. Bauer as Chairman of the Board
2010-02-17 08:06:45
Quote: Haro Hartounian, president and chief executive officer of Vyteris. "We welcome him to the Vyteris board and look forward to his contributions.""Vyteris' highly versatile and validated transdermal drug delivery technology has broad potential in multiple indications, with applications in the delivery of peptides and proteins and the ability to address complex drug delivery needs," stated Dr. Bauer. "The company has the opportunity to create significant value from this innovative technology through...Read article
Vyteris Announces Private Placement of $1.06 Million of Senior Subordinated Convertible Notes
2010-02-09 05:15:51
Quote: VYTRNews), developer of the
first FDA-approved active transdermal drug delivery system and a leader in
active transdermal drug delivery technology, announced today the private
placement of $1,060,000 of Senior Subordinated Convertible Promissory Notes
due 2013."This financing is a vote of confidence from investors in our strategic
plan," said Haro Hartounian, Ph.D., president and chief executive officer
of Vyteris."Over the past three months, our financial restructuring
efforts have raised a tot...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements
2010-02-09 05:15:50
Quote: Entry into a Material Definitive Agreement
On February 2, 2010, Vyteris, Inc. (the "Registrant") consummated a private
placement to accredited investors ("Investors") of $1,060,000 principal amount
of Senior Subordinated Convertible Promissory Notes due 2013 (the "Notes"). The
Notes bear no interest and are convertible into common stock of the Registrant
at the option of the Investors at an initial conversion price of $0.20 per
share. In addition, the Notes automat...Read article
Vyteris Announces Restructuring of Its Balance Sheet Through a $2.3 Million Non-Dilutive Capital Raise and Conversion of Approximately $20 Million of Debt and Preferred Shares Into Common Stock
2009-12-30 01:36:45
Quote: VYTRNews), developer of the
first FDA-approved active transdermal drug delivery system and a leader in
active transdermal drug delivery technology, announced today the sale of
$2.3 million of net operating tax losses in a non-dilutive capital raise
and the conversion of approximately $20 million of debt and preferred
shares into common stock through an agreement with Spencer Trask Specialty
Group LLC.These efforts were completed as part of the Company's ongoing
financial restructuring and overal...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financi
2009-12-30 01:36:44
Quote: Modification of Material Definitive Agreement
Amended Restructuring Agreement with Spencer Trask Specialty Group, LLC
On December 24, 2009, as part of Vyteris, Inc.'s (the "Company" or "Vyteris")
strategy to restructure its balance sheet, it entered into an Amendment to the
Restructuring Agreement with Spencer Trask Specialty Group, LLC and certain
affiliated entities ("STSG").
The principal terms of the Amended Agreement are as follows:
1. The principal amount o...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
2009-12-29 02:25:27
Quote: Termination of a Material Definitive Agreement
On December 21, 2009, Vyteris, Inc. (the "Company" or "Vyteris") received notice
from Ferring Pharmaceuticals, Inc. ("Ferring") of its termination of the License
and Development Agreement, dated September 30, 2004, by and between the Company
and Ferring ("Agreement"), effective 30 days from the date of the notice,
pursuant to Section 9.04 of the Agreement.
Pursuant to Section 9.05 of the Agreement, upon a ter...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 10-Q, Quarterly Report
2009-11-30 04:41:35
Quote: The terms "Company," "Vyteris," "us,"
"we" or "our" refer to each of Vyteris, Inc., its subsidiary, also named
Vyteris, Inc. (incorporated in the state of Delaware) and the combined company.
Liquidity
On June 30, 2009 our cash position was $0.2 million, with a working capital
deficit of $19.9 million. On June 30, 2009 we also had approximately $2.7
million in accounts payable which are more than 60 days past due. This trend is
expected to conti...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 10-Q, Quarterly Report
2009-11-30 04:41:35
Quote: Our actual results could differ materially from those anticipated
in the forward-looking statements as a result of a variety of factors, including
those discussed in "Risk Factors" and elsewhere in this Quarterly Report on Form
10-Q.
Overview
Vyteris, Inc. (formerly Vyteris Holdings (Nevada), Inc., (the terms "Vyteris"
and the "Company" refer to each of Vyteris, Inc., its subsidiary, Vyteris, Inc.
(incorporated in the State of Delaware) and the consolidated compan...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 8-K, Financial Statements and Exhibits
2009-11-30 04:41:35
Quote: VYTERIS HOLDINGS (NEVADA), INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
VYTERIS HOLDINGS (NEVADA), INC.
11-May-2009Financial Statements and ExhibitsPrivacy PolicyTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
2009-11-30 04:41:34
Quote: Amendment to a Material Definitive Agreement
On October 30, 2009, the Company, as part of its strategy to restructure its
balance sheet, entered into an Amendment and Waiver ("Amendment") to
Registration Rights Agreement (the "Registration Rights Agreement") dated
September 29, 2004 among Vyteris, Inc. (fka Treasure Mountain Holdings, Inc.),
Spencer Trask Ventures, Inc., Rodman & Renshaw, LLC, and various
shareholders. Pursuant to Section 6(f) of the Registration Rights ...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 8-K, Change in Directors or Principal Officers
2009-11-30 04:41:34
Quote: VYTERIS HOLDINGS (NEVADA), INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
VYTERIS HOLDINGS (NEVADA), INC.
29-Oct-2009Change in Directors or Principal OfficersPrivacy PolicyTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informationa...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements
2009-11-30 04:41:34
Quote: Restructuring Agreement with Spencer Trask Specialty Group, LLC
On October 1, 2009, Vyteris, Inc. (the "Company"), as part of the Company's
strategy to restructure its balance sheet, entered into a Restructuring
Agreement with Spencer Trask Specialty Group, LLC and certain affiliated
entities ("STSG"). The principal terms of the Restructuring Agreement are as
follows:
1. The principal amount of all indebtedness and accrued and unpaid interest
thereon owed by the Company to S...Read article
VYTERIS HOLDINGS (NEVADA), INC. Files SEC form 10-Q, Quarterly Report
2009-11-30 04:41:33
Quote: We have
implemented severe cost reduction measures, including headcount reductions,
abandoning our leased facility at 17-01 Pollitt Drive, Fair Lawn, NJ and
reducing the level of effort spent on research and development programs, other
than our female infertility treatment.
We raised $2.8 million through a loan from Ferring in July 2008 and December
2008, $2.5 million of which was satisfied in March 2009, through application of
the Phase II milestone payment otherwise due by Ferring to Vyteris, ...Read article
Would you like to leave a comment about Vyteris Inc. VYTR/VYTR.OB
Find out what social network information about Vyteris Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Vyteris Inc.'s Stock there is more great penny stock and market information at Realpennies